Actelion, being bought by J&J, says full year core net income rose 27 percent
Swiss drugmaker Actelion's 2016 core net income rose 27 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial hypertension (PAH), it said on Tuesday. Core net income rose to 881 million Swiss francs ($877.8 million) from 693 million francs in the previous year, the company said in a statement. Sales rose 18 percent to 2.42 billion francs, in line with the 2.41 billion francs expected in a Reuters poll.
The post Actelion, being bought by J&J, says full year core net income rose 27 percent appeared first on Health News Headlines - Yahoo News.